These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 25622075)

  • 1. Codelivery of sorafenib and curcumin by directed self-assembled nanoparticles enhances therapeutic effect on hepatocellular carcinoma.
    Cao H; Wang Y; He X; Zhang Z; Yin Q; Chen Y; Yu H; Huang Y; Chen L; Xu M; Gu W; Li Y
    Mol Pharm; 2015 Mar; 12(3):922-31. PubMed ID: 25622075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma.
    Hu B; Sun D; Sun C; Sun YF; Sun HX; Zhu QF; Yang XR; Gao YB; Tang WG; Fan J; Maitra A; Anders RA; Xu Y
    Biochem Biophys Res Commun; 2015 Dec; 468(4):525-32. PubMed ID: 26482853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticles of a polyaspartamide-based brush copolymer for modified release of sorafenib: In vitro and in vivo evaluation.
    Cervello M; Pitarresi G; Volpe AB; Porsio B; Balasus D; Emma MR; Azzolina A; Puleio R; Loria GR; Puleo S; Giammona G
    J Control Release; 2017 Nov; 266():47-56. PubMed ID: 28917533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin and curcumin co-loaded nano-liposomes for the treatment of hepatocellular carcinoma.
    Cheng Y; Zhao P; Wu S; Yang T; Chen Y; Zhang X; He C; Zheng C; Li K; Ma X; Xiang G
    Int J Pharm; 2018 Jul; 545(1-2):261-273. PubMed ID: 29730175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multifunctional pH-sensitive polymeric nanoparticles for theranostics evaluated experimentally in cancer.
    Liu Y; Feng L; Liu T; Zhang L; Yao Y; Yu D; Wang L; Zhang N
    Nanoscale; 2014 Mar; 6(6):3231-42. PubMed ID: 24500240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Therapy for Hepatocellular Carcinoma: Co-Delivery of Sorafenib and Curcumin Using Lactosylated pH-Responsive Nanoparticles.
    Bian Y; Guo D
    Drug Des Devel Ther; 2020; 14():647-659. PubMed ID: 32109990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
    Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
    Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preparation of an efficient and safe polymeric-magnetic nanoparticle delivery system for sorafenib in hepatocellular carcinoma.
    Tom G; Philip S; Isaac R; Praseetha PK; Jiji SG; Asha VV
    Life Sci; 2018 Aug; 206():10-21. PubMed ID: 29709652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma.
    Tang X; Chen L; Li A; Cai S; Zhang Y; Liu X; Jiang Z; Liu X; Liang Y; Ma D
    Drug Deliv; 2018 Nov; 25(1):1484-1494. PubMed ID: 29916268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex.
    Zhao R; Li T; Zheng G; Jiang K; Fan L; Shao J
    Biomaterials; 2017 Oct; 143():1-16. PubMed ID: 28755539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomacromolecule/lipid hybrid nanoparticles for controlled delivery of sorafenib in targeting hepatocellular carcinoma therapy.
    Zhang J; Wang T; Mu S; Olerile LD; Yu X; Zhang N
    Nanomedicine (Lond); 2017 Apr; 12(8):911-925. PubMed ID: 28339312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sorafenib and gadolinium co-loaded liposomes for drug delivery and MRI-guided HCC treatment.
    Xiao Y; Liu Y; Yang S; Zhang B; Wang T; Jiang D; Zhang J; Yu D; Zhang N
    Colloids Surf B Biointerfaces; 2016 May; 141():83-92. PubMed ID: 26844644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
    Hsu FT; Liu YC; Chiang IT; Liu RS; Wang HE; Lin WJ; Hwang JJ
    Int J Oncol; 2014 Jul; 45(1):177-88. PubMed ID: 24807012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
    You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T
    J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib.
    Zheng N; Liu W; Li B; Nie H; Liu J; Cheng Y; Wang J; Dong H; Jia L
    J Exp Clin Cancer Res; 2019 May; 38(1):232. PubMed ID: 31151472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptive immune cells are necessary for the enhanced therapeutic effect of sorafenib-loaded nanoparticles.
    Zhao ZB; Long J; Zhao YY; Yang JB; Jiang W; Liu QZ; Yan K; Li L; Wang YC; Lian ZX
    Biomater Sci; 2018 Mar; 6(4):893-900. PubMed ID: 29512660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic Antitumor Effect of Sorafenib in Combination with ATM Inhibitor in Hepatocellular Carcinoma Cells.
    Liu J; Liu Y; Meng L; Ji B; Yang D
    Int J Med Sci; 2017; 14(6):523-529. PubMed ID: 28638267
    [No Abstract]   [Full Text] [Related]  

  • 18. Codelivery of sorafenib and GPC3 siRNA with PEI-modified liposomes for hepatoma therapy.
    Sun W; Wang Y; Cai M; Lin L; Chen X; Cao Z; Zhu K; Shuai X
    Biomater Sci; 2017 Nov; 5(12):2468-2479. PubMed ID: 29106433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer.
    Yang S; Zhang B; Gong X; Wang T; Liu Y; Zhang N
    Int J Nanomedicine; 2016; 11():2329-43. PubMed ID: 27307733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
    Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
    Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.